Literature DB >> 8087172

The neurochemistry of vascular dementia.

C G Gottfries1, K Blennow, I Karlsson, A Wallin.   

Abstract

Vascular dementia (VAD) is cognitive impairment caused by changes in the blood circulation of the brain. It is not synonymous with multi-infarct dementia. The latter is a subgroup of VAD. Neurochemical investigations of noninfarcted brain tissue from patients with VAD show general changes in VAD brains. The serotonin metabolism is severely reduced and so is the activity of choline acetyltransferase. Monamine oxidase B is significantly increased in the white matter. A severe decrease in myelin components indicates white matter disturbances of such a degree that they must be considered to be of pathogenetic importance. The levels of some neuropeptides in the hypothalamus are increased. This is a finding which is in agreement with clinical findings of a high activity in the hypothalamic-pituitary-adrenal axis in patients with VAD. This high activity is possibly due to a loss of serotonergic inhibitory tone on the hypothalamus in VAD brains.

Entities:  

Mesh:

Year:  1994        PMID: 8087172     DOI: 10.1159/000106715

Source DB:  PubMed          Journal:  Dementia        ISSN: 1013-7424


  25 in total

1.  Cognitive function and cholinergic transmission in patients with subcortical vascular dementia and microbleeds: a TMS study.

Authors:  Raffaele Nardone; Pierpaolo De Blasi; Martin Seidl; Yvonne Höller; Francesca Caleri; Frediano Tezzon; Gunther Ladurner; Stefan Golaszewski; Eugen Trinka
Journal:  J Neural Transm (Vienna)       Date:  2011-04-24       Impact factor: 3.575

2.  Vascular cognitive impairment.

Authors:  Laura Pedelty; David L Nyenhuis
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-05

3.  Cerebrospinal fluid acetylcholine and choline in vascular dementia of Binswanger and multiple small infarct types as compared with Alzheimer-type dementia.

Authors:  H Tohgi; T Abe; M Kimura; M Saheki; S Takahashi
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  MR analysis of the substantia innominata in normal aging, Alzheimer disease, and other types of dementia.

Authors:  Haruo Hanyu; Tetsuichi Asano; Hirofumi Sakurai; Yuriko Tanaka; Masaru Takasaki; Kimihiko Abe
Journal:  AJNR Am J Neuroradiol       Date:  2002-01       Impact factor: 3.825

Review 5.  Cognitive impairment in acquired brain injury: a predictor of rehabilitation outcomes and an opportunity for novel interventions.

Authors:  Ellen Whyte; Elizabeth Skidmore; Howard Aizenstein; Joseph Ricker; Meryl Butters
Journal:  PM R       Date:  2011-06       Impact factor: 2.298

Review 6.  Use of Cholinesterase Inhibitors in Non-Alzheimer's Dementias.

Authors:  Paul Noufi; Rita Khoury; Sajeeka Jeyakumar; George T Grossberg
Journal:  Drugs Aging       Date:  2019-08       Impact factor: 3.923

Review 7.  Pharmacotherapy for Vascular Cognitive Impairment.

Authors:  Muhammad U Farooq; Jiangyong Min; Christopher Goshgarian; Philip B Gorelick
Journal:  CNS Drugs       Date:  2017-09       Impact factor: 5.749

Review 8.  Cholinesterase inhibitors and vascular dementia: another string to their bow?

Authors:  Roger Bullock
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 9.  Cholinergic deficiency involved in vascular dementia: possible mechanism and strategy of treatment.

Authors:  Juan Wang; Hai-Yan Zhang; Xi-Can Tang
Journal:  Acta Pharmacol Sin       Date:  2009-07       Impact factor: 6.150

Review 10.  Vascular dementia: prevention and treatment.

Authors:  Catherine McVeigh; Peter Passmore
Journal:  Clin Interv Aging       Date:  2006       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.